Literature DB >> 25537131

Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor.

Anthony Yiu-Ho Woo1,2, Ying Song1, Weizhong Zhu3, Rui-Ping Xiao1,4.   

Abstract

Seven-transmembrane receptors, also called GPCRs, represent the largest class of drug targets. Upon ligand binding, a GPCR undergoes conformational rearrangement and thereby changes its interaction with effector proteins including the cognate G-proteins and the multifunctional adaptor proteins, β-arrestins. These proteins, by initiating distinct signal transduction mechanisms, mediate one or several functional responses. Recently, the concept of ligand-directed GPCR signalling, also called functional selectivity or biased agonism, has been proposed to explain the phenomenon that chemically diverse ligands exhibit different efficacies towards the different signalling pathways of a single GPCR, and thereby act as functionally selective or 'biased' ligands. Current concepts support the notion that ligand-specific GPCR conformations are the basis of ligand-directed signalling. Multiple studies using fluorescence spectroscopy, X-ray crystallography, mass spectroscopy, nuclear magnetic resonance spectroscopy, single-molecule force spectroscopy and other techniques have provided the evidence to support this notion. It is anticipated that these techniques will ultimately help elucidate the structural basis of ligand-directed GPCR signalling at a precision meaningful for structure-based drug design and how a specific ligand molecular structure induces a unique receptor conformation leading to biased signalling. In this review, we will summarize recent advances in experimental techniques applied in the study of functionally selective GPCR conformations and breakthrough data obtained in these studies particularly those of the β2-adrenoceptor.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25537131      PMCID: PMC4667867          DOI: 10.1111/bph.13049

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  113 in total

Review 1.  Principles: receptor theory in pharmacology.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 2.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

3.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex.

Authors:  K A DeFea; Z D Vaughn; E M O'Bryan; D Nishijima; O Déry; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes.

Authors:  R P Xiao; X Ji; E G Lakatta
Journal:  Mol Pharmacol       Date:  1995-02       Impact factor: 4.436

5.  Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction.

Authors:  Ismayil Ahmet; Melissa Krawczyk; Weizhong Zhu; Anthony Yiu-Ho Woo; Christopher Morrell; Suresh Poosala; Riu-Ping Xiao; Edward G Lakatta; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-20       Impact factor: 4.030

6.  Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor.

Authors:  Michael Zocher; Juan J Fung; Brian K Kobilka; Daniel J Müller
Journal:  Structure       Date:  2012-06-28       Impact factor: 5.006

7.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

8.  Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.

Authors:  Anthony Yiu-Ho Woo; Tian-Bing Wang; Xiaokun Zeng; Weizhong Zhu; Darrell R Abernethy; Irving W Wainer; Rui-Ping Xiao
Journal:  Mol Pharmacol       Date:  2008-10-07       Impact factor: 4.436

9.  Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes.

Authors:  R P Xiao; P Avdonin; Y Y Zhou; H Cheng; S A Akhter; T Eschenhagen; R J Lefkowitz; W J Koch; E G Lakatta
Journal:  Circ Res       Date:  1999 Jan 8-22       Impact factor: 17.367

10.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more
  3 in total

1.  Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.

Authors:  Wei Xu; Xiaozhao Wang; Aaron M Tocker; Peng Huang; Maarten E A Reith; Lee-Yuan Liu-Chen; Amos B Smith; Sandhya Kortagere
Journal:  ACS Chem Neurosci       Date:  2016-11-23       Impact factor: 4.418

2.  Chinese innovation in cardiovascular drug discovery.

Authors:  Xin Wang; Yong Ji; Baofeng Yang
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

3.  Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility.

Authors:  Qingtong Wang; Ying Wang; Toni M West; Yongming Liu; Gopireddy R Reddy; Federica Barbagallo; Bing Xu; Qian Shi; Bingqing Deng; Wei Wei; Yang K Xiang
Journal:  Cardiovasc Res       Date:  2021-08-29       Impact factor: 10.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.